Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOR NASDAQ:BCLI NASDAQ:CSBR NASDAQ:GMDA NASDAQ:PTE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCLIBrainstorm Cell Therapeutics$0.69-2.8%$0.75$0.52▼$3.97$7.84M0.15554,911 shs4,775 shsCSBRChampions Oncology$6.42-33.6%$10.15$3.60▼$11.99$96.03M0.5133,852 shs32,633 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics+0.54%-8.94%+13.51%-41.32%-82.21%CSBRChampions Oncology-10.74%+5.55%+5.73%-16.05%+40.30%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCLIBrainstorm Cell Therapeutics$0.69-2.8%$0.75$0.52▼$3.97$7.84M0.15554,911 shs4,775 shsCSBRChampions Oncology$6.42-33.6%$10.15$3.60▼$11.99$96.03M0.5133,852 shs32,633 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics+0.54%-8.94%+13.51%-41.32%-82.21%CSBRChampions Oncology-10.74%+5.55%+5.73%-16.05%+40.30%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/ABCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ACSBRChampions Oncology 3.00Buy$12.0086.80% UpsideGMDAGamida Cell 0.00N/AN/AN/APTEPolarityTE 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTE, ACOR, BCLI, CSBR, and GMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025BCLIBrainstorm Cell TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACSBRChampions Oncology$56.94M1.55$0.42 per share15.20$0.26 per share24.71GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00PTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/ABCLIBrainstorm Cell Therapeutics-$11.62M-$3.10N/AN/AN/AN/AN/A-519.50%11/13/2025 (Estimated)CSBRChampions Oncology$4.70M-$0.0634.85∞N/A5.19%87.76%9.95%N/AGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/APTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/ALatest PTE, ACOR, BCLI, CSBR, and GMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/15/2025Q1 2026CSBRChampions OncologyN/A-$0.03N/A-$0.03N/A$13.99 million7/23/2025Q4 2025CSBRChampions OncologyN/A-$0.13N/A-$0.13N/A$12.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCLIBrainstorm Cell TherapeuticsN/A0.210.21CSBRChampions OncologyN/A0.930.94GMDAGamida Cell213.142.162.09PTEPolarityTEN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCLIBrainstorm Cell Therapeutics14.33%CSBRChampions Oncology41.30%GMDAGamida Cell50.34%PTEPolarityTE11.75%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCLIBrainstorm Cell Therapeutics11.15%CSBRChampions Oncology46.98%GMDAGamida Cell3.40%PTEPolarityTE5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableCSBRChampions Oncology14313.78 million7.31 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionablePTEPolarityTE427.38 million6.98 millionOptionablePTE, ACOR, BCLI, CSBR, and GMDA HeadlinesRecent News About These CompaniesPioneering Technology Reports 2025 Q3 Financial ResultsAugust 29, 2025 | thenewswire.comTPolarityTE’s SkinTE: A Promising Solution for Diabetic Foot UlcersJuly 11, 2025 | tipranks.comCommodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to a Convertible Loan AgreementJuly 2, 2025 | globenewswire.comCommodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private PlacementJuly 2, 2025 | globenewswire.comPioneering Technology Reports 2025 Q2 Financial ResultsMay 30, 2025 | thenewswire.comTMomentum Builds for ScanTech AI Systems at PTE Madrid 2025 as Industry Embraces AI-Powered SecurityApril 9, 2025 | globenewswire.comRegenetp Inc RGTPQApril 18, 2024 | morningstar.comMNEW INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PolarityTE, Inc. & Encourages Inves...January 10, 2024 | br.advfn.comRegenETP, Inc. (NJT.SG)January 6, 2024 | finance.yahoo.comPolarityTE Inc. [PTE] Investment Appeal on the RiseJune 14, 2023 | knoxdaily.comKPolarityTE Stock (NASDAQ:PTE), DividendsJune 9, 2023 | benzinga.comPolarityTE shares are trading lower after the company filed voluntary petitions for relief under Chapter 11.June 7, 2023 | benzinga.comPolarityTE, Inc. (PTE) stock price, news, quote & history – Yahoo FinanceMay 15, 2023 | uk.finance.yahoo.comSkin Replacement Market Recent Technological Advancements to ... - Digital JournalMay 4, 2023 | news.google.comNDismissal of Securities Claims Against Utah Biotech Company ... - JD SupraApril 29, 2023 | news.google.comNPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You ... - NasdaqApril 25, 2023 | news.google.comNPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 25, 2023 | finance.yahoo.comPolarityTE Avoids Lawsuit Over Skin Graft Product Disclosures - Bloomberg LawApril 20, 2023 | news.google.comNChronic Wound Care Market is expected to reach a valuation of US ... - Digital JournalApril 12, 2023 | news.google.comNForm DEF 14A ENERGY FUELS INC - StreetInsider.comApril 5, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025Top 5 September Stock Picks: Market Tailwinds Drive New MomentumBy Thomas Hughes | September 1, 2025What to Expect From the Q3 Reporting SeasonBy Thomas Hughes | September 3, 20253 Gold ETFs That Could Surge If the Fed Cuts Rates This MonthBy Jordan Chussler | September 1, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025PTE, ACOR, BCLI, CSBR, and GMDA Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Brainstorm Cell Therapeutics NASDAQ:BCLI$0.69 -0.02 (-2.82%) As of 02:49 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
